Premaitha Health PLC Notice of results & appointment of broker (6624K)
September 23 2016 - 2:50AM
UK Regulatory
TIDMNIPT
RNS Number : 6624K
Premaitha Health PLC
23 September 2016
Premaitha Health plc
("Premaitha" or the "Company")
Notice of results & appointment of broker
Manchester, UK - 23 September 2016 - Premaitha Health plc (AIM:
NIPT), developer of the leading CE-marked complete non-invasive
prenatal screening system, makes the following announcements:
Notice of Results
Premaitha will publish its financial results for the year ended
31 March 2016 by Friday 30 September 2016. The Company will
recognise in these accounts a significant increase in the provision
relating to its litigation with Illumina in respect of the robust
defence being mounted by Premaitha. The annual report will be
posted on the Company's website and distributed to shareholders
shortly thereafter, along with an AGM notice.
Appointment of Broker
Premaitha also announces that it has appointed finnCap Ltd as
sole broker to the Company. Cairn Financial Advisers LLP remains as
Nominated Adviser to the Company.
The information contained within this announcement constitutes
inside information stipulated under the Market Abuse Regulation
(EU) No. 596/2014.
For more information, please contact:
Premaitha Health plc Tel: +44 (0)
161 667 6865
Dr Stephen Little, Chief Executive
Office
Barry Hextall, Chief Financial
Officer
Joanne Cross, Head of Marketing
investors@premaitha.com
Cairn Financial Advisers LLP (Nomad) Tel: +44 (0)
20 7148 7900
Liam Murray
finnCap (Broker) Tel: +44 (0)
20 7220 0500
Adrian Hargrave / Scott Mathieson
(Corporate Finance)
Tony Quirke (Corporate Broking)
Vigo Communications Tel: +44 (0)
20 7830 9704
Ben Simons / Fiona Henson / Antonia
Pollock
premaitha@vigocomms.com
About Premaitha
Premaitha is a molecular diagnostics company which uses the
latest advances in DNA analysis technology to develop safer, faster
and regulatory approved non-invasive screening tests for pregnant
women.
Premaitha's lead test - the IONA(R) test - was launched in
February 2015 and is the leading CE-marked complete system which
estimates the risk of a fetus being affected with Down's syndrome
or other genetic conditions. The IONA(R) test is performed on the
mother's blood sample - which contains traces of fetal DNA - and
then analysed using next generation DNA sequencing technology from
ThermoFisher Scientific.
Unlike existing prenatal screening methods, due to its high
level of accuracy, the IONA(R) test can significantly reduce the
number of women subjected to unnecessary stressful and invasive
follow up diagnostic procedures which are costly, resource
intensive and carry a risk of miscarriage.
Non-invasive prenatal screening is an emerging, multi-billion
dollar global market and Premaitha's CE-marked complete system
enables laboratories and healthcare practitioners to offer an
approved, non-invasive prenatal screening solution in-house.
Premaitha is based in Manchester Science Park, United Kingdom
and its shares trade on the AIM market of the London Stock Exchange
(AIM: NIPT). For further information please visit
www.premaitha.com. Follow us on twitter @PremaithaHealth.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORUOSBRNAAKURR
(END) Dow Jones Newswires
September 23, 2016 03:50 ET (07:50 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From May 2023 to May 2024